Evidence record
Dexamethasone × COVID-19
Glucocorticoid-mediated suppression of cytokine storm in severe COVID-19.
Why this drug?
The RECOVERY trial demonstrated mortality benefit in hospitalized COVID-19 patients requiring oxygen, establishing dexamethasone as standard-of-care anti-inflammatory therapy in severe disease.
Known risks
- Hyperglycemia
- Immunosuppression and infection risk
- Adrenal suppression with prolonged use
- Mood changes and insomnia
Evidence behind this
28-day mortality reduction in patients requiring oxygen; no benefit in mild disease.
Mechanism
Glucocorticoid-mediated suppression of cytokine storm in severe COVID-19.
Authoritative sources
AI-generated summary
The RECOVERY trial provided definitive evidence for dexamethasone 6 mg daily in hospitalized COVID-19 patients on supplemental oxygen or ventilation. WHO and NIH guidelines endorse this indication.
- RECOVERY Collaborative Group, NEJM 2021
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.